Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | BRAF | P15056 | 2/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.54 |
| ▸ | TUBB | P07437 | 3/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.54 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.54 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.54 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.54 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9189846 | 0.83 | MAPT (0.60) | MAPTBRAFTUBB4ATUBBTUBA3C | |
| SCHEMBL6796229 | 0.80 | MAPT (0.62) | MAPTBRAFMEN1LMNAKMT2A | |
| SCHEMBL12963403 | 0.79 | TUBB1 (0.58) | MAPTHDAC1TUBB4ATUBBTUBA3C | |
| SCHEMBL9190510 | 0.79 | TUBB4A (0.77) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6817059 | 0.78 | MAPT (0.62) | MAPTBRAFMEN1LMNAKMT2A | |
| SCHEMBL6815042 | 0.78 | MAPT (0.59) | MAPTHDAC1TUBB4ATUBBTUBA3C | |
| SCHEMBL11935942 | 0.78 | CYP19A1 (0.61) | MAPTHDAC1TUBB4ATUBBTUBA3C | |
| SCHEMBL5841682 | 0.77 | TUBB4A (0.59) | MAPTHDAC1TUBB4ATUBBTUBA3C | |
| SCHEMBL1065537 | 0.76 | HDAC1 (0.66) | HDAC1HPGDALDH1A1KDM4EALOX15 | |
| SCHEMBL1065539 | 0.76 | HDAC1 (0.66) | HDAC1HPGDALDH1A1KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167087-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | claimed |
| EP-1606247-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. Lundbeck A/S (DK) | 2005-12-21 | — | — | EP | claimed |
| WO-2004080950-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-23 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20060167087-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| EP-1606247-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. Lundbeck A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080950-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167087-A1 | Substituted aniline derivatives | CYP3A43, UGT2B7, CYP3A7 | MAPT 860/4885HDAC1 775/4885BRAF 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.